{"entity":{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","aka":[],"tldr":"Strand makes programmable messenger RNA medicines that switch on only inside tumours. Its first drug is injected into a tumour and makes cells there produce an immune-boosting signal.","summary":"Strand Therapeutics is a clinical-stage mRNA company. Its platform combines SignalPath lipid nanoparticles for delivery beyond the liver, SignalLock microRNA-sensing circuits that activate the RNA in target tissue and silence it elsewhere, and SignalScript self-replicating and circular RNA for potency and durability. Lead programme STX-001 is a lipid nanoparticle-encapsulated self-replicating mRNA encoding interleukin-12, given intratumourally in advanced solid tumours; the IND cleared in January 2024, the first patient was dosed in May 2024 and initial phase 1 results were presented at ASCO 2025, with the company reporting complete responses. STX-003, a systemic tumour programme using SignalLock, is planned to enter the clinic in 2026, and STX-005 is an in vivo CAR-T programme for autoimmune disease and blood cancers. Strand raised a USD 52 million Series A (2021), USD 45 million Series A1 (2022) and USD 153 million Series B (August 2025).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.strandtx.com"},{"label":"News and articles (Series B and STX-001 data)","url":"https://www.strandtx.com/articles"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy","in-vivo-car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06249048","nct07751042"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series B investors are not named on the fetched company page; the Business Wire release could not be fetched (blocked). HQ inferred from Boston Business Journal awards referenced on the site. Founding year not sourced."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.strandtx.com","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2021,"amountUsd":52000000,"source":"https://www.strandtx.com/articles"},{"round":"Series A","year":2022,"amountUsd":45000000,"source":"https://www.strandtx.com/articles","note":"Series A1 extension"},{"round":"Series B","year":2025,"amountUsd":153000000,"source":"https://www.strandtx.com/articles"}]},"route":"/companies/strand-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"trial":[{"id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/"},{"id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/"}]}}